VISION 2020: The Right to Sight – India has released the revised National Guidelines for the Management of Diabetic ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

November is observed as Diabetic Eye Disease Awareness Month, a month dedicated to educating people about the serious eye ...

Diabetic eye damage can begin early, even before diagnosis, silently threatening vision. Early screenings and lifestyle ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

India has introduced revised national guidelines aimed at reducing blindness caused by diabetic retinopathy, a complication of diabetes affecting millions of Indians.

A long-time supporter of the St John Eye Van, UD Trucks has been formally recognised for its support of the vital regional ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Diabetes is a systemic disease, which means it affects many organs, including the heart, blood vessels, nerves, kidneys and ...

A key protein, LRG1, was identified as the early cause of diabetic eye damage, and blocking it may stop the disease before ...